[go: up one dir, main page]

NZ507967A - Substituted indolinones having an inhibiting effect on kinases and cycline/CDK complexes - Google Patents

Substituted indolinones having an inhibiting effect on kinases and cycline/CDK complexes

Info

Publication number
NZ507967A
NZ507967A NZ507967A NZ50796799A NZ507967A NZ 507967 A NZ507967 A NZ 507967A NZ 507967 A NZ507967 A NZ 507967A NZ 50796799 A NZ50796799 A NZ 50796799A NZ 507967 A NZ507967 A NZ 507967A
Authority
NZ
New Zealand
Prior art keywords
cycline
kinases
inhibiting effect
cdk complexes
substituted indolinones
Prior art date
Application number
NZ507967A
Inventor
Rainer Walter
Wolfgang Grell
Meel Jacobus Constantinus Van
Norbert Redemann
Armin Heckel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NZ507967A publication Critical patent/NZ507967A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Substituted indolines and isomers and salts thereof, of general formula (I) wherein; X is O or S; R1 is H, alkoxycarbonyl or alkanoyl; R2 is carboxy, alkoxycarboxy or an optionally substituted aminocarbonyl; R3 is an optionally substituted phenyl or naphthyl; R4 is H or alkyl; R5 is H, optionally substituted alkyl, indanyl, heteroaryl, pyrrolidinyl, piperidinyl, phenyl, pyridyl, pyrimidyl, or thienyl. Also described is a pharmaceutical composition of formula (I).
NZ507967A 1998-04-15 1999-04-10 Substituted indolinones having an inhibiting effect on kinases and cycline/CDK complexes NZ507967A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816624A DE19816624A1 (en) 1998-04-15 1998-04-15 Novel substituted indolinones, their preparation and their use as pharmaceuticals
PCT/EP1999/002436 WO1999052869A1 (en) 1998-04-15 1999-04-10 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Publications (1)

Publication Number Publication Date
NZ507967A true NZ507967A (en) 2003-04-29

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507967A NZ507967A (en) 1998-04-15 1999-04-10 Substituted indolinones having an inhibiting effect on kinases and cycline/CDK complexes

Country Status (31)

Country Link
EP (1) EP1071665B1 (en)
JP (1) JP4015365B2 (en)
KR (1) KR100588250B1 (en)
CN (1) CN100338036C (en)
AR (1) AR015763A1 (en)
AT (1) ATE251138T1 (en)
AU (1) AU749829B2 (en)
BG (1) BG64443B1 (en)
BR (1) BR9909688A (en)
CA (1) CA2323111C (en)
CO (1) CO5011040A1 (en)
DE (2) DE19816624A1 (en)
DK (1) DK1071665T3 (en)
EA (1) EA003532B1 (en)
EE (1) EE04432B1 (en)
ES (1) ES2207209T3 (en)
HU (1) HUP0101568A3 (en)
ID (1) ID26420A (en)
IL (1) IL138036A0 (en)
MY (1) MY122357A (en)
NO (1) NO317298B1 (en)
NZ (1) NZ507967A (en)
PL (1) PL343314A1 (en)
PT (1) PT1071665E (en)
SK (1) SK283824B6 (en)
TR (1) TR200002980T2 (en)
TW (1) TW510897B (en)
UA (1) UA63009C2 (en)
WO (1) WO1999052869A1 (en)
YU (1) YU59800A (en)
ZA (1) ZA200004623B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
DE19924401A1 (en) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE50012136D1 (en) * 1999-08-27 2006-04-13 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
PE20030062A1 (en) 2001-05-30 2003-02-08 Sugen Inc ARALKYLSULFONIL-3- (PYRROL-2-ILMETILIDEN) -2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
DE60318188T2 (en) 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield GLUCOCORTICOID MIMETICS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USE
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
DE10237423A1 (en) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
JP4949845B2 (en) 2003-10-03 2012-06-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Fluorescent probes for use in protein kinase inhibitor binding assays
DE102004012070A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
JP2008525525A (en) 2004-12-27 2008-07-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Glucocorticoid mimetic, its production, pharmaceutical composition and use
EP1891008B1 (en) * 2005-06-10 2010-06-30 Merck Patent GmbH Oxindoles as kinase inhibitors
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
CA2671990A1 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
AU2009256289A1 (en) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
CN104039761A (en) 2011-11-14 2014-09-10 利亘制药公司 Methods and compositions associated with the granulocyte colony-stimulating factor receptor
US9962370B2 (en) * 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (en) * 2017-04-28 2019-07-09 西安医学院 A kind of 3- (morpholine replaces fragrant imido grpup) Benzazole compounds and its preparation method and application
CN111285872B (en) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 Indole-2-ketone derivative and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament

Also Published As

Publication number Publication date
BG104813A (en) 2001-08-31
EA200001021A1 (en) 2001-06-25
KR20010042731A (en) 2001-05-25
BR9909688A (en) 2000-12-19
SK283824B6 (en) 2004-02-03
CA2323111A1 (en) 1999-10-21
PL343314A1 (en) 2001-08-13
ZA200004623B (en) 2001-05-30
ES2207209T3 (en) 2004-05-16
EE04432B1 (en) 2005-02-15
HUP0101568A3 (en) 2002-12-28
CN100338036C (en) 2007-09-19
NO317298B1 (en) 2004-10-04
AU749829B2 (en) 2002-07-04
WO1999052869A1 (en) 1999-10-21
EP1071665B1 (en) 2003-10-01
CO5011040A1 (en) 2001-02-28
BG64443B1 (en) 2005-02-28
TW510897B (en) 2002-11-21
DE19816624A1 (en) 1999-10-21
ID26420A (en) 2000-12-21
EP1071665A1 (en) 2001-01-31
SK15132000A3 (en) 2001-03-12
KR100588250B1 (en) 2006-06-13
HUP0101568A2 (en) 2001-09-28
EE200000598A (en) 2002-04-15
YU59800A (en) 2003-04-30
NO20005151D0 (en) 2000-10-13
ATE251138T1 (en) 2003-10-15
PT1071665E (en) 2004-02-27
MY122357A (en) 2006-04-29
UA63009C2 (en) 2004-01-15
CN1297438A (en) 2001-05-30
JP2002511449A (en) 2002-04-16
DK1071665T3 (en) 2004-01-05
CA2323111C (en) 2009-09-15
AR015763A1 (en) 2001-05-16
EA003532B1 (en) 2003-06-26
NO20005151L (en) 2000-10-13
AU3814999A (en) 1999-11-01
DE59907199D1 (en) 2003-11-06
IL138036A0 (en) 2001-10-31
JP4015365B2 (en) 2007-11-28
TR200002980T2 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
NZ507967A (en) Substituted indolinones having an inhibiting effect on kinases and cycline/CDK complexes
NZ536734A (en) Spiroindolinepiperidine derivatives
GB9801690D0 (en) Therapeutic agents
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
HUP0101599A2 (en) Heterocyclically substituted amides, process for producing them, use of them and pharmaceutical compositions containing them
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
GB2392154B (en) Protein Kinase Inhibitors
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
IL156873A0 (en) Pharmaceutically active piperidine derivatives
AP2001002172A0 (en) Substituted pyrazoles as p38 kinase inhibitors
HK1080470A1 (en) Heterocyclic compounds
IL165262A0 (en) Kinase inhibitors
GB0124933D0 (en) Chemical compounds
AU6294298A (en) Matrix metalloproteinase inhibitors
AU7127794A (en) 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives as 5ht1a ligands
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL164613A0 (en) Thienyl compounds
MXPA02004440A (en) Pyrrole derivatives as phosphodiesterase vii inhibitors.
MXPA02012054A (en) Tetracyclic diketopiperazine compounds as pdev inhibitors.
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
BG104575A (en) Matrix metalloprotease inhibitors
TW200504059A (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0203302D0 (en) Novel Compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)